These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 27086878)

  • 21. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.
    Johnson TN; Rostami-Hodjegan A
    Paediatr Anaesth; 2011 Mar; 21(3):291-301. PubMed ID: 20497354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical pharmacokinetics in veterinary medicine.
    Baggot JD
    Clin Pharmacokinet; 1992 Apr; 22(4):254-73. PubMed ID: 1606786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A framework for meta-analysis of veterinary drug pharmacokinetic data using mixed effect modeling.
    Li M; Gehring R; Lin Z; Riviere J
    J Pharm Sci; 2015 Apr; 104(4):1230-9. PubMed ID: 25641543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The application of physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling for exploring risk assessment approaches of chemical mixtures.
    Yang RS; el-Masri HA; Thomas RS; Constan AA; Tessari JD
    Toxicol Lett; 1995 Sep; 79(1-3):193-200. PubMed ID: 7570656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utilization of Physiologically Based Pharmacokinetic Modeling in Pharmacokinetic Study of Natural Medicine: An Overview.
    Jia Q; He Q; Yao L; Li M; Lin J; Tang Z; Zhu X; Xiang X
    Molecules; 2022 Dec; 27(24):. PubMed ID: 36557804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perspectives in pharmacokinetics. Physiologically based pharmacokinetic modeling as a tool for drug development.
    Charnick SB; Kawai R; Nedelman JR; Lemaire M; Niederberger W; Sato H
    J Pharmacokinet Biopharm; 1995 Apr; 23(2):217-29. PubMed ID: 8719238
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Physiologically based pharmacokinetic-quantitative systems toxicology and safety (PBPK-QSTS) modeling approach applied to predict the variability of amitriptyline pharmacokinetics and cardiac safety in populations and in individuals.
    Tylutki Z; Mendyk A; Polak S
    J Pharmacokinet Pharmacodyn; 2018 Oct; 45(5):663-677. PubMed ID: 29943290
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A paradigm shift in pharmacokinetic-pharmacodynamic (PKPD) modeling: rule of thumb for estimating free drug level in tissue compared with plasma to guide drug design.
    Poulin P
    J Pharm Sci; 2015 Jul; 104(7):2359-68. PubMed ID: 25943586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Physiologically based pharmacokinetic modeling for nanoparticle toxicity study.
    Li M; Reineke J
    Methods Mol Biol; 2012; 926():369-82. PubMed ID: 22975976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of Mequindox and Its Marker Residue 1,4-Bisdesoxymequindox in Swine Following Multiple Oral Gavage and Intramuscular Administration: An Experimental Study Coupled with Population Physiologically Based Pharmacokinetic Modeling.
    Zeng D; Lin Z; Fang B; Li M; Gehring R; Riviere JE; Zeng Z
    J Agric Food Chem; 2017 Jul; 65(28):5768-5777. PubMed ID: 28640606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physiologically based pharmacokinetic model use in risk assessment--Why being published is not enough.
    McLanahan ED; El-Masri HA; Sweeney LM; Kopylev LY; Clewell HJ; Wambaugh JF; Schlosser PM
    Toxicol Sci; 2012 Mar; 126(1):5-15. PubMed ID: 22045031
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: prediction of plasma concentration-time profiles in human by using the physiologically-based pharmacokinetic modeling approach.
    Poulin P; Jones RD; Jones HM; Gibson CR; Rowland M; Chien JY; Ring BJ; Adkison KK; Ku MS; He H; Vuppugalla R; Marathe P; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Yates JW
    J Pharm Sci; 2011 Oct; 100(10):4127-57. PubMed ID: 21541937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PBPK modeling and simulation in drug research and development.
    Zhuang X; Lu C
    Acta Pharm Sin B; 2016 Sep; 6(5):430-440. PubMed ID: 27909650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Have physiologically-based pharmacokinetic models delivered?
    Edginton AN; Joshi G
    Expert Opin Drug Metab Toxicol; 2011 Aug; 7(8):929-34. PubMed ID: 21762039
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimation of residue depletion of cyadox and its marker residue in edible tissues of pigs using physiologically based pharmacokinetic modelling.
    Huang L; Lin Z; Zhou X; Zhu M; Gehring R; Riviere JE; Yuan Z
    Food Addit Contam Part A Chem Anal Control Expo Risk Assess; 2015; 32(12):2002-17. PubMed ID: 26414219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The successes and failures of physiologically based pharmacokinetic modeling: there is room for improvement.
    Poggesi I; Snoeys J; Van Peer A
    Expert Opin Drug Metab Toxicol; 2014 May; 10(5):631-5. PubMed ID: 24517185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study.
    Yoon M; Kedderis GL; Yan GZ; Clewell HJ
    Toxicology; 2015 Jun; 332():52-66. PubMed ID: 24863738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physiologically based pharmacokinetic (PBPK) modeling in children.
    Barrett JS; Della Casa Alberighi O; Läer S; Meibohm B
    Clin Pharmacol Ther; 2012 Jul; 92(1):40-9. PubMed ID: 22669290
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physiologically Based Pharmacokinetic Modeling and Allometric Scaling in Pediatric Drug Development: Where Do We Draw the Line?
    Johnson TN; Ke AB
    J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S83-S93. PubMed ID: 34185901
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mathematical modeling and simulation in animal health. Part III: Using nonlinear mixed-effects to characterize and quantify variability in drug pharmacokinetics.
    Bon C; Toutain PL; Concordet D; Gehring R; Martin-Jimenez T; Smith J; Pelligand L; Martinez M; Whittem T; Riviere JE; Mochel JP
    J Vet Pharmacol Ther; 2018 Apr; 41(2):171-183. PubMed ID: 29226975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.